For improving the efficacy of EGFRvIII-targeting CAR-T without inducing off-targeting toxicity, a humanised antibody M27 was developed to specifically bind to both wild-type EGFR- and EGFRvIII-overexpressing tumour cells (177). This evidence concerns the gene EGFR and neoplasm.